Risk Factors for Complications Associated with Peripherally Inserted Central Catheters During Induction Chemotherapy for Acute Myeloid Leukemia

Intern Med. 2022 Apr 1;61(7):989-995. doi: 10.2169/internalmedicine.8184-21. Epub 2021 Sep 11.

Abstract

Objective Peripherally inserted central catheters (PICCs) are widely used in patients with hematologic malignancies. However, the risks of PICC-related complications during chemotherapy for acute myeloid leukemia (AML) are not fully understood. Methods We conducted a retrospective review of 128 adult patients with AML who received induction therapy by way of PICC insertion between 2012 and 2019. Results The median duration of PICC insertion was 30 days. The incidence rate of catheter-related bloodstream infection (CRBSI) was 2.4% at 30 days, and women were more likely to suffer from CRBSI than men. Local reactions at the insertion site were observed in 56 patients; however, these events did not predict CRBSI. The incidence rates of catheter-related thrombosis (CRT) were 1.6% at 30 days. Obesity put patients at an increased risk for CRT. Unexpected PICC removal occurred in 59 patients, and women were at a higher risk of catheter removal than men. Conclusion Low PICC-related complication rates, possibly associated with high rates of catheter removal, were observed during intensive chemotherapy for AML. Women and obese patients require careful monitoring of their PICC. Procedures to achieve appropriate PICC removal without increasing the complication rate need to be considered.

Keywords: CRBSI; PICC; catheter-related thrombosis.

MeSH terms

  • Adult
  • Catheter-Related Infections* / epidemiology
  • Catheter-Related Infections* / etiology
  • Catheterization, Central Venous* / adverse effects
  • Catheterization, Peripheral* / adverse effects
  • Catheters / adverse effects
  • Central Venous Catheters* / adverse effects
  • Female
  • Humans
  • Induction Chemotherapy / adverse effects
  • Leukemia, Myeloid, Acute* / complications
  • Leukemia, Myeloid, Acute* / epidemiology
  • Leukemia, Myeloid, Acute* / therapy
  • Male
  • Retrospective Studies
  • Risk Factors